JC Syngeneic Model Overview
The JC syngeneic model is a well-characterized murine breast carcinoma system derived from a spontaneous mammary tumor in BALB/c mice. It represents a moderately differentiated, non-metastatic form of mammary adenocarcinoma and provides a reproducible, immune-competent platform for evaluating anti-tumor immune responses, cytokine modulation, and combination immunotherapy. When implanted orthotopically into the mammary fat pad of BALB/c mice, JC cells form solid, moderately growing tumors that remain largely localized, with limited or no spontaneous metastasis.
The JC model preserves a functional immune system, making it suitable for investigations of tumor immunogenicity, immune editing, and checkpoint blockade response in early-stage mammary carcinoma. Because of its reproducible growth kinetics and intermediate aggressiveness, this model is frequently used to explore immune cell infiltration, tumor microenvironment reprogramming, and the synergistic effects of immunotherapeutics combined with cytotoxic or radiation-based treatments.
Request a Custom Quote for JC Syngeneic ModelBiological and Molecular Characteristics
The JC cell line originates from a spontaneous mammary adenocarcinoma in BALB/c mice and displays an epithelial morphology with cohesive cellular architecture. It is classified as a triple-negative model, lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. JC tumors exhibit moderate proliferation, strong adhesion, and limited invasiveness relative to more aggressive BALB/c-derived lines such as 4T1. The tumor microenvironment demonstrates a balanced immune cell composition, including macrophages, lymphocytes, and fibroblasts, which collectively modulate the tumor’s immunological responsiveness.
The molecular profile of JC tumors reveals moderate expression of matrix metalloproteinases (MMP-2 and MMP-9), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β), supporting local angiogenesis and stromal remodeling. Cytokine analysis shows upregulation of interleukins such as IL-6 and IL-10, which play roles in immune tolerance and tumor progression. These characteristics make the JC model an effective intermediate system for evaluating therapeutic approaches that target immune regulation and microenvironmental signaling.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous mammary carcinoma (mouse) |
| Receptor status | ER– / PR– / HER2– |
| Inoculation route | Orthotopic (mammary fat pad) or subcutaneous |
| Tumor take rate | >90% |
| Doubling time | Approximately 4–5 days in vivo |
| Metastatic potential | Low; typically non-metastatic |
| Immunophenotype | Mixed macrophage and lymphocyte infiltration |
| Common applications | Immunotherapy, radiation studies, cytokine modulation research |
In Vivo Model Development and Tumorigenicity
In vivo establishment of the JC syngeneic model is achieved through orthotopic or subcutaneous implantation of tumor cells into BALB/c mice. Orthotopic implantation results in consistent primary tumor formation within 7–10 days after inoculation, with a high take rate and predictable growth kinetics. JC tumors expand locally without significant metastatic dissemination, enabling controlled analysis of immune response dynamics and localized therapeutic efficacy.
This model provides a robust framework for investigating tumor-host immune equilibrium, immune activation following checkpoint inhibition, and the influence of cytokine signaling on tumor progression. Because of its moderate growth rate, the JC model allows for extended study durations and longitudinal immune monitoring. It is also frequently used in comparative studies alongside other BALB/c-derived mammary carcinoma models to delineate the role of tumor aggressiveness in determining immunotherapeutic sensitivity.
Request a Custom Quote for JC Syngeneic ModelHistopathology and Immunohistochemical Profile
Histologically, JC tumors exhibit well-differentiated epithelial morphology with compact cell clusters surrounded by fibrous connective tissue. The lesions demonstrate moderate vascularization and limited necrosis, reflecting their relatively stable and localized growth pattern. The tumor stroma contains an active population of fibroblasts, macrophages, and lymphocytes, contributing to an immunologically responsive microenvironment.
Immunohistochemical evaluation reveals moderate Ki-67 expression, consistent with controlled proliferative activity. CD3 and CD8 staining identify T-cell infiltration within both the tumor parenchyma and peritumoral zones, while F4/80 and CD11b staining confirm macrophage and myeloid cell presence. PD-L1 expression varies among individual tumors but is typically low to moderate, supporting its use in checkpoint inhibition studies that aim to enhance local immune activation. The histological and immunohistochemical profile of JC tumors provides a balanced platform for testing immunomodulatory strategies under physiologically relevant immune conditions.
Preclinical Applications and Drug Response
The JC syngeneic model has long served as a versatile system for preclinical breast cancer research. It is widely used to evaluate immunotherapeutic regimens, including checkpoint inhibitors, cytokine-based therapies, and combination protocols involving radiation or chemotherapy. Due to its intact immune system and moderate growth kinetics, the JC model allows detailed temporal analysis of immune cell recruitment, cytokine release, and the establishment of immunological memory following treatment.
Anti-PD-1 and anti-CTLA-4 therapies have demonstrated measurable tumor growth inhibition in JC-bearing mice, often accompanied by increased infiltration of CD8⁺ T cells and a shift toward a pro-inflammatory cytokine milieu. Radiation-based studies have revealed that local irradiation enhances antigen presentation and immune recognition, synergizing with checkpoint blockade to induce durable tumor control. The JC model’s reproducibility, immune accessibility, and moderate aggressiveness make it a valuable system for evaluating new immunomodulatory agents and studying the interplay between tumor biology and host immune function.
Request This Model
To request the JC syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for JC Syngeneic Model